Key Takeaways Madrigal posted a Q3 loss of $5.08 per share, wider than the expected $1.98 loss.Rezdiffra sales hit $287.3M, surpassing estimates and fueling strong investor response.EU approval and new licensing moves reinforce Madrigal's expanding MASH franchise.Madrigal Pharmaceuticals (MDGL) reported third-quarter 2025 loss of $5.08 per share, wider than the Zacks Consensus Estimate of a loss of $1.98. In the year-ago quarter, the company had incurred a loss of $4.92 per share.During the quarter, the com ...

The company has also made strategic moves to strengthen its pipeline and market position. Madrigal entered a global licensing agreement with CSPC Pharma to incorporate an oral GLP-1 into its offerings. Additionally, a new Orange Book listed patent for Rezdiffra extends its protection until 2045. The launch of Rezdiffra in Germany following European Commission approval further expands its market reach. Financially, Madrigal has a negative P/E ratio of -35.13, reflecting its current lack of profitability. How ...

NASDAQ: MDGL © 2025 Madrigal Pharmaceuticals, Inc. All rights reserved. Forward-looking Statements This presentation includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it but are subject to factors beyond its control. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regar ...

Third-quarter 2025 Rezdiffra™ (resmetirom) net sales of $287.3 millionAs of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra providing protection into 2045 Launched Rezdiffra in Germany following European Commission approval Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion as of Sept. 30, 2025Company to host conference call today, Nov ...

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the impact of Rezdiffra interruption on patients, underscoring the need for continued treatment to prevent disease progressionFurther poster presentations examine early real-world experience with Rezdiffra and the clinical burden of MASH CONSHOHOCKEN, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Madr ...

CONSHOHOCKEN, Pa., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its third-quarter 2025 financial results on Tuesday, Nov. 4, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financi ...

CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on October 1, 2025 to 27 new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan. The equity awards were approved by Madrigal's independent Compensation Committee in accordance with Nasd ...

Madrigal Pharmaceuticals (NASDAQ: MDGL ) has quickly become a major player in metabolic liver disease treatments with Rezdiffra (resmetirom), which is indicated for F2-F3 MASH. This drug was authorized under accelerated approval in the US and is already showing blockbuster potential. This is despite havingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohi ...

Madrigal Pharmaceuticals (NASDAQ: MDGL ) has quickly become a major player in metabolic liver disease treatments with Rezdiffra (resmetirom), which is indicated for F2-F3 MASH. This drug was authorized under accelerated approval in the US and is already showing blockbuster potential. This is despite havingMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohi ...

公司活动安排 - 公司将于2025年9月8日美东时间上午7:45参加摩根士丹利第23届全球医疗健康大会 [1] - 会议演示将通过网络直播进行 直播回放将在活动结束后提供 [1] 公司业务聚焦 - 公司专注于开发代谢功能障碍相关脂肪性肝炎的新型疗法 该疾病存在高度未满足医疗需求 [2] - 核心产品Rezdiffra为每日一次口服肝脏导向THR-β激动剂 针对MASH关键病因 [2] 产品竞争优势 - Rezdiffra是首个且唯一获得FDA和欧盟委员会批准的治疗中度至晚期纤维化MASH的药物（F2至F3阶段） [2] - 正在进行针对代偿性MASH肝硬化（F4c阶段）的第三阶段临床结果试验 [2]